SG11201507934PA - Peptide compound - Google Patents

Peptide compound

Info

Publication number
SG11201507934PA
SG11201507934PA SG11201507934PA SG11201507934PA SG11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA
Authority
SG
Singapore
Prior art keywords
peptide compound
peptide
compound
Prior art date
Application number
SG11201507934PA
Inventor
Taiji Asami
Ayumu Niida
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of SG11201507934PA publication Critical patent/SG11201507934PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201507934PA 2013-05-28 2014-05-27 Peptide compound SG11201507934PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013111893 2013-05-28
PCT/JP2014/002772 WO2014192284A1 (en) 2013-05-28 2014-05-27 Peptide compound

Publications (1)

Publication Number Publication Date
SG11201507934PA true SG11201507934PA (en) 2015-10-29

Family

ID=50942304

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507934PA SG11201507934PA (en) 2013-05-28 2014-05-27 Peptide compound

Country Status (36)

Country Link
US (2) US10087229B2 (en)
EP (1) EP3004155B1 (en)
JP (2) JP6429799B2 (en)
KR (1) KR102229051B1 (en)
CN (1) CN105209485B (en)
AP (1) AP2015008781A0 (en)
AR (1) AR096440A1 (en)
AU (1) AU2014272500B2 (en)
CA (1) CA2908581C (en)
CL (1) CL2015003031A1 (en)
CY (1) CY1124790T1 (en)
DK (1) DK3004155T3 (en)
DO (1) DOP2015000261A (en)
EA (2) EA035813B1 (en)
EC (1) ECSP15044389A (en)
ES (1) ES2900744T3 (en)
GE (1) GEP201706762B (en)
HK (1) HK1216757A1 (en)
HR (1) HRP20212014T1 (en)
HU (1) HUE057361T2 (en)
IL (1) IL242005B (en)
LT (1) LT3004155T (en)
MA (1) MA38472B1 (en)
MX (2) MX2015015464A (en)
MY (1) MY172744A (en)
PE (1) PE20151770A1 (en)
PH (1) PH12015502391A1 (en)
PL (1) PL3004155T3 (en)
PT (1) PT3004155T (en)
SG (1) SG11201507934PA (en)
SI (1) SI3004155T1 (en)
TN (1) TN2015000451A1 (en)
TW (1) TWI638831B (en)
UA (1) UA118558C2 (en)
UY (1) UY35589A (en)
WO (1) WO2014192284A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3004155T1 (en) 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptide compound
JOP20200119A1 (en) 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
CN104846061A (en) * 2015-05-07 2015-08-19 中国药科大学 Method for determining receptor affinity of GLP-1 receptor agonist
CN105388239B (en) * 2015-12-18 2018-01-05 兆科药业（合肥）有限公司 A kind of monitoring method of Solid-phase synthesis peptides
JP6995042B2 (en) * 2016-05-24 2022-02-04 武田薬品工業株式会社 Peptide compound
EP3551202B1 (en) 2016-12-06 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Peptide compound
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3743092A4 (en) 2018-01-23 2021-10-20 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
ES2961384T3 (en) 2018-05-04 2024-03-11 Novo Nordisk As Derivatives of GIP and their uses
CN110818771B (en) * 2018-08-14 2023-01-17 陈铭 Carbonyl sulfide mediated polypeptide synthesis using amino acid ionic liquids
JP2022503793A (en) * 2018-09-24 2022-01-12 武田薬品工業株式会社 GIP receptor agonist peptide compound and its use
EP3856339A1 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2021034815A1 (en) * 2019-08-19 2021-02-25 Eli Lilly And Company Methods of making incretin analogs
KR20210040818A (en) 2019-10-04 2021-04-14 한미약품 주식회사 Composition of Glucagon and Dual GLP-1/GIP receptor agonist, and therapeutic use thereof
CN110684082B (en) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 GIP and GLP-1 dual-agonist polypeptide compound, pharmaceutically acceptable salt and application
EP4126921A2 (en) * 2020-03-25 2023-02-08 Takeda Pharmaceutical Company Limited Qd dosing of gip receptor agonist peptide compounds and uses thereof
CA3184717A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonists at glp-1 and gip receptors suitable for oral delivery
EP4185606A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Glp-1 and gip receptor co-agonists
WO2022253202A1 (en) 2021-06-01 2022-12-08 南京知和医药科技有限公司 Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
TW202330584A (en) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 Prodrugs and uses thereof
CN117402219A (en) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 GLP-1/GIP double agonist and preparation method and application thereof
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
AU4863797A (en) 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
WO1999047161A1 (en) 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
US7368427B1 (en) 1998-12-07 2008-05-06 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas GLP-1 analogues
AU2001256757B2 (en) 2000-05-16 2006-03-09 Sanwa Kagaku Kenkyusho Co., Ltd. Agents for preventing or ameliorating insulin resistance and/or obesity
CA2490564A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
EP2210900A3 (en) 2003-12-16 2010-08-11 Ipsen Pharma Analogues of GLP-1
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
WO2006136374A2 (en) 2005-06-20 2006-12-28 Develogen Aktiengesellschaft Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells
JP2009542813A (en) 2006-07-11 2009-12-03 ハルクネスス プハルマセウティカルス，インコーポレイテッド How to treat obesity with satiety factor
JP5399244B2 (en) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー DPP-IV resistant GIP hybrid polypeptide with selectable properties
TWI430806B (en) 2006-09-13 2014-03-21 Smithkline Beecham Corp Methods for administering long-lasting hypoglycemic agents
EP1972349A1 (en) 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP2224945B1 (en) 2007-11-23 2012-05-16 Michael Rothkopf Methods of enhancing diabetes resolution
KR20110040760A (en) * 2008-06-17 2011-04-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip-based mixed agonists for treatment of metabolic disorders and obesity
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
PL2373681T3 (en) 2008-12-10 2017-07-31 Glaxosmithkline Llc Pharmaceutical compositions of albiglutide
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
WO2011002066A1 (en) 2009-07-02 2011-01-06 武田薬品工業株式会社 Peptide and use thereof
BR112012018585A2 (en) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp antagonist-gon agonist glucagon compositions and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (en) 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
AU2011348202A1 (en) 2010-12-22 2013-07-04 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
KR102002783B1 (en) * 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
RS59977B1 (en) 2011-06-10 2020-03-31 Novo Nordisk As Polypeptides
US20130090285A1 (en) 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
US9758560B2 (en) 2011-09-06 2017-09-12 Novo Nordisk A/S GLP-1 derivatives
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
TR201815338T4 (en) 2012-05-03 2018-11-21 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods.
CN104519902B (en) 2012-05-08 2017-10-27 诺和诺德股份有限公司 Double derivatives of acylated GLP 1
WO2013192310A1 (en) 2012-06-19 2013-12-27 Massachusetts Institute Of Technology Mass production and size control of nanoparticles through controlled microvortices
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
CN104583233B (en) 2012-06-21 2018-10-23 印第安纳大学研究及科技有限公司 Show the analog of the glucagon of GIP receptor actives
JP2016503046A (en) 2012-12-19 2016-02-01 ノヴォ ノルディスク アー／エス Novel GLP-1 receptor agonist having cholesterol efflux activity
MA38276B1 (en) 2012-12-21 2018-03-30 Sanofi Sa Derivatives of exendin 4 for use in the treatment of metabolic syndrome disorders, including diabetes and obesity, as well as the reduction of excessive dietary intake.
EP3238734A1 (en) 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
SI3004155T1 (en) 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptide compound
JP2017503474A (en) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ Glucagon-GLP-1-GIP triple agonist compound
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
JP2018012644A (en) 2014-11-26 2018-01-25 武田薬品工業株式会社 Peptide compound

Also Published As

Publication number Publication date
JP2016520511A (en) 2016-07-14
EA202090593A3 (en) 2020-08-31
TN2015000451A1 (en) 2017-04-06
KR20160010446A (en) 2016-01-27
BR112015027596A2 (en) 2017-12-05
EA035813B1 (en) 2020-08-14
CA2908581A1 (en) 2014-12-04
CA2908581C (en) 2021-07-13
PH12015502391B1 (en) 2016-02-22
AU2014272500A1 (en) 2015-11-05
EA201591891A1 (en) 2016-01-29
US9200051B2 (en) 2015-12-01
DK3004155T3 (en) 2022-01-03
IL242005B (en) 2019-05-30
CN105209485B (en) 2019-12-10
EP3004155A1 (en) 2016-04-13
US20160052988A1 (en) 2016-02-25
KR102229051B1 (en) 2021-03-16
ES2900744T3 (en) 2022-03-18
US10087229B2 (en) 2018-10-02
MX2015015464A (en) 2016-03-21
MA38472A1 (en) 2018-01-31
LT3004155T (en) 2021-12-27
CL2015003031A1 (en) 2016-06-24
DOP2015000261A (en) 2015-12-31
UA118558C2 (en) 2019-02-11
AU2014272500B2 (en) 2018-03-08
PL3004155T3 (en) 2022-02-07
TWI638831B (en) 2018-10-21
NZ712421A (en) 2021-04-30
MA38472B1 (en) 2018-09-28
HUE057361T2 (en) 2022-05-28
ECSP15044389A (en) 2017-08-31
UY35589A (en) 2014-12-31
EP3004155B1 (en) 2021-11-24
MX2019010531A (en) 2019-10-15
JP6570705B2 (en) 2019-09-04
PE20151770A1 (en) 2015-12-11
GEP201706762B (en) 2017-10-25
PH12015502391A1 (en) 2016-02-22
JP2018168167A (en) 2018-11-01
SI3004155T1 (en) 2022-02-28
AR096440A1 (en) 2015-12-30
HRP20212014T1 (en) 2022-04-01
CY1124790T1 (en) 2022-11-25
EA202090593A2 (en) 2020-06-30
TW201514203A (en) 2015-04-16
WO2014192284A1 (en) 2014-12-04
JP6429799B2 (en) 2018-11-28
HK1216757A1 (en) 2016-12-02
AP2015008781A0 (en) 2015-10-31
PT3004155T (en) 2021-12-22
US20140357552A1 (en) 2014-12-04
MY172744A (en) 2019-12-11
CN105209485A (en) 2015-12-30

Similar Documents

Publication Publication Date Title
HK1216757A1 (en) Peptide compound
EP2960234A4 (en) Trk-INHIBITING COMPOUND
GB201302368D0 (en) Compound
HRP20180452T1 (en) Peptides
EP2982674A4 (en) Pyridinylpyrazoloquinoline compound
HUE050164T2 (en) Novel four-ctl epitope-joined peptide
EP2947066A4 (en) Phenoxyalkylamine compound
HK1211596A1 (en) Peptide
HK1211595A1 (en) Peptide
HK1198769A1 (en) Novel peptide
GB201315130D0 (en) Peptides
GB201307331D0 (en) Compound
GB201319776D0 (en) Compound
GB201316660D0 (en) Peptides
GB201315772D0 (en) Compound
GB201300381D0 (en) Peptides
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound